Levact

Bendamustine Hydrochloride, the active ingredient in Levact, is an alkylating agent presented as an intravenous solution for infusion use. It is employed in the treatment of certain hematologic malignancies, specifically chronic lymphocytic leukemia and non‑Hodgkin lymphoma, in adult patients. It is indicated for patients who have not responded adequately to first‑line therapies and is administered under specialist supervision.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical product to hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and clinical use.

Levact (bendamustine hydrochloride) is used in the management of mature B‑cell malignancies. - Chronic lymphocytic leukemia: improves remission rates and disease control in adult patients. - Non‑Hodgkin lymphoma: provides therapeutic benefit in indolent and aggressive subtypes. - Mantle cell lymphoma: offers an effective option for patients with relapsed or refractory disease.

Adverse reactions may occur with Levact administration.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels causing bruising. - Fever: occasional low‑grade temperature elevation. - Anemia: decreased red blood cell count leading to weakness.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress. - Secondary malignancies: emergence of new cancers after treatment. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances. - Anaphylaxis: acute allergic reaction with hypotension and airway compromise.

Careful monitoring and patient assessment are essential when using Levact. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess hepatic function: evaluate liver enzymes before and during therapy. - Evaluate renal function: adjust use in patients with impaired clearance. - Avoid use in active severe infection: postpone treatment until resolved. - Use effective contraception: prevent pregnancy during and after treatment. - Store at controlled room temperature: keep in original packaging, protect from light and moisture.

Bendamustine may interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., azole antifungals): may increase bendamustine exposure. - Live vaccines: risk of infection due to immunosuppression. - Concurrent alkylating agents: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., certain statins): may require dose adjustment. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.